Register now for the 24th Annual John Goldman Conference on CML: Biology and Therapy

October 21-23, 2022 - Mandelieu - La Napoule (France)
Chairs: J. Cortes, T.P. Hughes, D.S. Krause

Registration is now open
Click here to register for the meeting

Contact: camille.dufour@univ-paris-diderot.fr

Program Highlights:

• Janet Rowley Prize award ceremony: recipient Oliver Hantschel (Marburg)
• John Goldman Prize award ceremony: recipient Andreas Hochhaus (Jena)
• iCMLf Prize award ceremony: Jan Geissler (Munich), Giora Sharf (Netanya)
  
  
• Special Lecturers: 
  - Carlo Maley (Tempe)
  - Jyoti Nangalia (Cambridge)
  - Toni Ribas (Los Angeles)
  - Andreas Trumpp (Heidelberg)
  
  
• Workshop for Non-Clinical Scientists #1
  Oncology/Hematology degraders - Degradation as a strategy against cancer
  Chairs: Oliver Hantschel (Marburg), Vignir Helgason (Glasgow)
  Speakers: George Burslem (Philadelphia), Stefan Knapp (Frankfurt), Charles Mullighan (Memphis)
• Workshop for Non-Clinical Scientists #2
  3D Genomics and nuclear organization
  Chairs: Michael Deininger (Milwaukee), Jerry Radich (Seattle)
  Speakers: Steven Eacker (Seattle), Aristotelis Tsirigos (New York), Greg Wang (Chapel Hill)
  
  
• Michele Baccarani Special Symposium
  Collaborative research in CML
  Chair: Giuseppe Saglio (Turin)
  Speakers: Rüdiger Hehlmann (Mannheim), Fausto Castagnetti (Bologna), Simona Soverini (Bologna), Susan Branford (Adelaide), François-Xavier Mahon (Bordeaux), Ehab Attalah (Milwaukee)
  
  
• Debate #1
  Is ponatinib still the drug of choice for 3rd line therapy?
  Chair: Tim P. Hughes (Adelaide)
  Speakers: Jorge Cortes (Augusta), Delphine Réa (Paris)
  
  
• Debate #2
  What is most important for CML persistence of the disease? Extrinsic factors or intrinsic factors?
  Chair: Ravi Bhatia (Birmingham)
  Speakers: Daniela Krause (Frankfurt), Mirle Schemionek-Reinders (Aachen)
  
  
• Meet the Expert Sessions
  Understanding Biology of Leukemia / Practical implication of multimix appoaches in leukemia – Charles Mullighan (Memphis)
  Leukemic stem cell biology – Andreas Trumpp (Heidelberg)
  New frontiers in drug development in cancer – Stefann Knapp (Frankfurt)
  Management of advance stage CML – Maihri Copland (Glasgow)
  Challenging scenarios for TFR – Susanne Saussele (Mannheim)
  Management of TKI adverse event – Jeff Lipton (Toronto)
  

The full program will be available soon.

Presentation of data at this conference will not jeopardize acceptance of the same at the following ASH congress.